Your Messages Inbox
Your Article Summary
See Latest ArticlesCovidien Submits Label Change for Optimark Contrast Agent
Covidien, 11/10/09
Covidien, a leading global provider of healthcare products, announced that it will voluntarily contraindicate the use of its Optimark gadoversetamide injection, a gadolinium–based contrast agent, in magnetic resonance imaging procedures involving patients with severe renal impairment. The Company is modifying the product's label to reflect a contraindication for this small patient population, which constitutes less than 0.5 percent of the U.S. population.
Today in Medical Devices/Products...keeping you current
Receive free subspecialty "5-minute updates" via email
AstraZeneca submits US New Drug Application for ticagrelor, an investigational antiplatelet agent
AstraZeneca, 11/23/09
FDA Grants Emergency Use Authorization of the Prodesse ProFlu-ST(TM)
Gen-Probe, 10/30/09
Gyrus PlasmaKinetic bipolar coagulation device for liver resection
Australian and New Zealand Journal of Surgery, 11/13/09
Article Search
Sponsor